Short interest for Appian gives investors a sense of the degree to which investors are betting on the decline of Appian's stock. Short interest data is updated every two weeks.

Appian Stock (NASDAQ:APPN), Short Interest Report

Appian

Appian is a low-code enterprise platform-as-a-service company focusing on business process management. The Appian platform is an integrated automation platform providing tools for organizations to design, automate, and optimize end-to-end processes and complex business operations. Capabilities include case management, robotic process automation, artificial intelligence, data fabric, and process mining. Most of Appian's revenue is subscription based with the remainder from services, with much of its subscription revenue being derived from its cloud-based platform, Appian Cloud.

2d,Rendering,Cloud,Computing,,Cloud,Computing,Concept

Earnings

News

Guidance

Movers

Tech

APPN

ROBT

SKYY

Appian Corp reported 11% Y/Y revenue growth in Q1 2024, slightly beating analyst consensus. EPS loss of $(0.24) missed expectations. Stock price dropped 9%.

Cloud Computing Firm Appian Stock Nosedives After Q1 Print, What&#39;s Going On?

Etsy photo by Sergei Elagin on Shutterstock

Pre-Market Outlook

Markets

Trading Ideas

CTMX

DASH

EBAY

ETSY

FRSH

FSLY

HDSN

PAYC

QRVO

RELY

SDGR

WOLF

Etsy Reports Downbeat Earnings, Joins Fastly, DoorDash And Other Big Stocks Moving Lower In Thursday&#39;s Pre-Market Session

Penny Stocks

Small Cap

Intraday Update

AMWL

AUPH

CETY

CGNX

CHNR

CNVS

DNOW

DTSS

DWAC

ELWS

EPAM

EXPR

FROG

IFBD

INFA

INOD

JXJT

LYFT

MANU

NNOX

NSIT

ORGS

PEGA

PENN

PLCE

PTEN

RNLX

ROMA

RVSN

SABR

SHAK

SLVM

SOUN

SPWR

TELO

TWLO

UDMY

ULBI

UPXI

ZBRA

Shares of  Herbalife Ltd. (NYSE: HLF) fell sharply in today’s session following weak quarterly earnings.

Why Herbalife Shares Are Trading Lower By Around 36%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Appian Corporation - Class A Common Stock

Appian Corp

<p>Green Plains (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPRE#NASDAQ">GPRE</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $36.6, with a high estimate of $55.00 and a low estimate of $22.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.4%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715011270_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The standing of Green Plains among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Strelzik</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$22.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Craig Irwin</td>
<td>Roth MKM</td>
<td>Lowers</td>
<td>Buy</td>
<td>$40.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$35.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Craig Irwin</td>
<td>Roth MKM</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Manav Gupta</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$31.00</td>
<td>$33.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Green Plains. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Green Plains compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Green Plains's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Green Plains's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/GPRE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Green Plains analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering Green Plains: A Closer Look</h2>
<p>Green Plains Inc manufactures and sells ethanol and ethanol byproducts in three segments based on function. The ethanol production segment, which generates the majority of revenue, includes the production of ethanol, distillers grains, Ultra-High Protein and renewable corn oil. The agribusiness and energy services segment includes grain handling and storage, commodity marketing and merchant trading for company-produced and third-party ethanol, distillers grains, Ultra-High Protein, renewable corn oil, natural gas and other commodities. The partnership segment provides fuel storage and transportation services.</p>
<h3>Breaking Down Green Plains's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Green Plains faced challenges, resulting in a decline of approximately <strong>-22.06%</strong> in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> Green Plains's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>1.02%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>0.87%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Green Plains's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>0.37%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Green Plains's debt-to-equity ratio is below the industry average at <strong>0.8</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

GPRE

Analyst Expectations For Green Plains's Future

<p>Analysts' ratings for Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) over the last quarter vary from bullish to bearish, as provided by 23 analysts.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">17</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $146.3, a high estimate of $190.00, and a low estimate of $125.00. Experiencing a 7.08% decline, the current average is now lower than the previous average price target of $157.44. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715011262_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The standing of Expedia Group among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trevor Young</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$138.00</td>
<td>$158.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$125.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Tom White</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$135.00</td>
<td>$152.00</td>
</tr>
<tr>
<td>Kevin Kopelman</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$130.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$128.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$137.00</td>
<td>$149.00</td>
</tr>
<tr>
<td>Naved Khan</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$190.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$140.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Mark Mahaney</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Daniel Kurnos</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>-</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$125.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Jed Kelly</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$155.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>James Lee</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$135.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Brian Pitz</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$145.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$145.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Jed Kelly</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$130.00</td>
<td>-</td>
</tr>
<tr>
<td>John Colantuoni</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$145.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$136.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$155.00</td>
<td>-</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$155.00</td>
<td>$159.00</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$130.00</td>
<td>-</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Neutral</td>
<td>$156.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Expedia Group. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Expedia Group compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Expedia Group's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Expedia Group's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EXPE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Expedia Group analyst ratings.</strong></a></p>
<h2>About Expedia Group</h2>
<p>Expedia is the world's second-largest online travel agency by bookings, offering services for lodging (80% of total 2023 sales), air tickets (3%), rental cars, cruises, in-destination, and other (11%), and advertising revenue (6%). Expedia operates a number of branded travel booking sites, but its three core onlint travel agency brands are Expedia, Hotels.com, and Vrbo. It also has a metasearch brand, Trivago. Transaction fees for online bookings account for the bulk of sales and profits.</p>
<h3>Expedia Group: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Expedia Group's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately <strong>0.07%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-4.67%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Expedia Group's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-11.14%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-0.58%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Expedia Group's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>7.37</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


EXPE

Cracking The Code: Understanding Analyst Reviews For Expedia Group

<p>During the last three months, 4 analysts shared their evaluations of ATI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATI#NYSE">ATI</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for ATI, revealing an average target of $63.5, a high estimate of $70.00, and a low estimate of $56.00. This upward trend is evident, with the current average reflecting a 19.07% increase from the previous average price target of $53.33.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715011254_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>A comprehensive examination of how financial experts perceive ATI is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Strauss</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$70.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Philip Gibbs</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$58.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Scott Deuschle</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Philip Gibbs</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$56.00</td>
<td>$49.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to ATI. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of ATI compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for ATI's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of ATI's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ATI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on ATI analyst ratings.</strong></a></p>
<h2>All You Need to Know About ATI</h2>
<p>ATI Inc supplies specialty metals to various end markets, including aerospace and defense, oil and gas, automotive, and electrical energy, among many others. The company's operating segment includes High-Performance Materials and Components and Advanced Alloys and Solutions. The majority of revenue is from the High-Performance Materials segment. The High-Performance Materials segment is focused on a wide range of high-performance specialty materials, parts, and components for several major end markets, including the aerospace &amp; defense, medical, and energy markets. Geographically, it operates in the United States, China, the United Kingdom, Germany, France, Canada, and Others, the majority is from the United States.</p>
<h3>Unraveling the Financial Story of ATI</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> ATI displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately <strong>0.46%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> ATI's net margin is impressive, surpassing industry averages. With a net margin of <strong>6.34%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>5.01%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>1.35%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>1.72</strong>, caution is advised due to increased financial risk.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


A Closer Look at 4 Analyst Recommendations For ATI

<p>TD Cowen  analyst Joshua Jennings   maintains PROCEPT BioRobotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>) with a Buy and raises the price target from $65 to $75.</p>


Price Target

PRCT

TD Cowen Maintains Buy on PROCEPT BioRobotics, Raises Price Target to $75

<p>Tenaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TS#NYSE">TS</a>) has outperformed the market over the past 20 years by 1.19% on an annualized basis producing an average annual return of 9.21%. Currently, Tenaris has a market capitalization of $19.42 billion. </p>
<p><strong>Buying $100 In TS:</strong> If an investor had bought $100 of TS stock 20 years ago, it would be worth <strong>$583.59</strong> today based on a price of $33.88 for TS at the time of writing.</p>
<h3>Tenaris's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715011245_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much $100 Invested In Tenaris 20 Years Ago Would Be Worth Today

<p>Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) has outperformed the market over the past 5 years by 8.46% on an annualized basis producing an average annual return of 20.75%. Currently, Deere has a market capitalization of $112.73 billion. </p>
<p><strong>Buying $100 In DE:</strong> If an investor had bought $100 of DE stock 5 years ago, it would be worth <strong>$257.61</strong> today based on a price of $404.97 for DE at the time of writing.</p>
<h3>Deere's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715011240_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much $100 Invested In Deere 5 Years Ago Would Be Worth Today

<p>8 analysts have expressed a variety of opinions on Fate Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATE#NASDAQ">FATE</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $7.25, a high estimate of $10.00, and a low estimate of $6.00. This current average has increased by 81.25% from the previous average price target of $4.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715011238_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive Fate Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$7.00</td>
<td>-</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$7.00</td>
<td>-</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$6.00</td>
<td>$2.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$7.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Ulz</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$7.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$7.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Peter Lawson</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$7.00</td>
<td>$3.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Fate Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Fate Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Fate Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Fate Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FATE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Fate Therapeutics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind Fate Therapeutics</h2>
<p>Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.</p>
<h3>Fate Therapeutics: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Fate Therapeutics faced challenges, resulting in a decline of approximately <strong>-96.22%</strong> in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-2632.58%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Fate Therapeutics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-11.44%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-8.4%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.28</strong>, Fate Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


FATE

Forecasting The Future: 8 Analyst Projections For Fate Therapeutics

<p>Adient (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADNT#NYSE">ADNT</a>) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $38.83, a high estimate of $46.00, and a low estimate of $33.00. A 7.17% drop is evident in the current average compared to the previous average price target of $41.83. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715011229_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The perception of Adient by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colin Langan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$33.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Ryan Brinkman</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Dan Levy</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$37.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>John Murphy</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$46.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Ryan Brinkman</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Colin Langan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$41.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Adient. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Adient compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Adient's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Adient's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ADNT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Adient analyst ratings.</strong></a></p>
<h2>All You Need to Know About Adient</h2>
<p>Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment into this new company. Adient is the leading seating supplier to the industry with about one third of the global market. Its share in China is now nearly 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated seating revenue from joint ventures after factoring in the sale was about $3.8 billion in fiscal 2023 and consolidated China revenue was $1.4 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2023 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $15.4 billion.</p>
<h3>Understanding the Numbers: Adient's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Adient's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately <strong>-1.05%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Adient's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>0.55%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Adient's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>0.89%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Adient's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>0.21%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>1.11</strong>, Adient faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ADNT

6 Analysts Have This To Say About Adient

<p><strong>Encompass Health's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHC#NYSE">EHC</a>) short percent of float has risen 6.49% since its last report. The company recently reported that it has <strong>2.47 million shares sold short</strong>, which is 2.79% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 3.41 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Encompass Health Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715011225_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Encompass Health has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Encompass Health's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Encompass Health's peer group average for short interest as a percentage of float is 9.22%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Peering Into Encompass Health's Recent Short Interest

<p><strong>TeraWulf's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NYSE">WULF</a>) short percent of float has risen 5.2% since its last report. The company recently reported that it has <strong>39.67 million shares sold short</strong>, which is 17.4% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.5 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>TeraWulf Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715011219_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for TeraWulf has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing TeraWulf's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, TeraWulf's peer group average for short interest as a percentage of float is 6.39%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


WULF

How Is The Market Feeling About TeraWulf?

<p>During the last three months, 6 analysts shared their evaluations of nVent Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVT#NYSE">NVT</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for nVent Electric, revealing an average target of $82.5, a high estimate of $91.00, and a low estimate of $72.00. Witnessing a positive shift, the current average has risen by 15.87% from the previous average price target of $71.20.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715011215_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The analysis of recent analyst actions sheds light on the perception of nVent Electric by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joe Ritchie</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$87.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Vladimir Bystricky</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$91.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Joe Ritchie</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$77.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Nicole Deblase</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$83.00</td>
<td>-</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$72.00</td>
<td>$65.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to nVent Electric. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of nVent Electric compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of nVent Electric's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of nVent Electric's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NVT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on nVent Electric analyst ratings.</strong></a></p>
<h2>Delving into nVent Electric's Background</h2>
<p>nVent Electric PLC is a provider of electrical connection and protection solutions. The company segments include Enclosures, Thermal Management, and Electrical and Fastening Solutions. It generates maximum revenue from the Enclosures segment. The Enclosures segment provides inventive solutions that protect, connect, and manage heat in critical electronics, communication, control, and power equipment. Geographically, it derives a majority of its revenue from North America. The company serves the Commercial and Residential, Energy, Industrial Solutions, and Infrastructure industries. Its products include Cabinets and Electronic Packaging, Electrical Fasteners, Hangers and Support, Concrete Reinforcing Steel Connections, Data Center and Networking Systems, and others.</p>
<h3>nVent Electric: Delving into Financials</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Positive Revenue Trend:</strong> Examining nVent Electric's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>16.13%</strong> as of 31 December, 2023, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.</p>
<p><strong>Net Margin:</strong> nVent Electric's net margin is impressive, surpassing industry averages. With a net margin of <strong>29.6%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> nVent Electric's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>8.38%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> nVent Electric's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>4.22%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.61</strong>, nVent Electric adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


In-Depth Examination Of 6 Analyst Recommendations For nVent Electric

<p><strong>Royal Gold's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGLD#NYSE">RGLD</a>) short percent of float has risen 21.56% since its last report. The company recently reported that it has <strong>2.67 million shares sold short</strong>, which is 6.09% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 6.34 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Royal Gold Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715011213_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Royal Gold has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Royal Gold's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Royal Gold's peer group average for short interest as a percentage of float is 2.37%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


RGLD

Looking Into Royal Gold's Recent Short Interest

Options

BlackLine Option Alert: Jun 21 $62.5 Calls at the Ask: 4500 @ $3.59 vs 133 OI; Earnings 5/7 After Close Ref=$60.325

<p>BTIG  analyst Justin Zelin   downgrades Lyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) from Buy to Neutral.</p>


Downgrades

LYRA

BTIG Downgrades Lyra Therapeutics to Neutral

<p>Barclays  analyst Adam Seiden   maintains MasTec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) with a Overweight and raises the price target from $106 to $130.</p>


Barclays Maintains Overweight on MasTec, Raises Price Target to $130

<p><a href="https://money.udn.com/money/story/5612/7944385">https://money.udn.com/money/story/5612/7944385</a> (Translated)</p>
<p>&nbsp;</p>
<p>AI application perianth exfoliation, two major AI giants Whida （NVIDIA）, ultra-micro（AMD）Full sprint high-efficiency operation （HPC）Market, outgoing package（2330）Today, next year CoWoS and SoIC advanced packaging capacity, assist station power generation AI related business orders heat transfer.</p>
<p>&nbsp;</p>
<p>The power generation height of the station is optimistic about the kinetic energy brought by AI-related applications. President Wei Zhejia repaired the visibility of AI orders and the revenue-to-income ratio at the French-speaking conference in April. Among them, the visibility of orders increased from 2027 to 2028.</p>
<p>&nbsp;</p>
<p>TSMC believes that the server AI processor's contribution revenue will grow more than double this year, accounting for the company's 2024 total revenue of ten-digit low segment （low-teens） percentage, and it is expected that the annual composite growth rate of the server AI processor will reach 50%, will account for more than 20% of TSMC revenue in 2028%.</p>


"The Advanced Encapsulation Capacity Of TSMC Is Booked To Whida, Ultra-Micro All The Way To Next Year" - Money.udn

<p>BTIG  analyst Peter Saleh   maintains Shake Shack (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>) with a Buy and raises the price target from $120 to $125.</p>


BTIG Maintains Buy on Shake Shack, Raises Price Target to $125

<p>Barclays  analyst Theresa Chen   maintains Marathon Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>) with a Overweight and lowers the price target from $221 to $195.</p>


Barclays Maintains Overweight on Marathon Petroleum, Lowers Price Target to $195

<p>Barclays  analyst Dan Levy   maintains Magna International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGA#NYSE">MGA</a>) with a Equal-Weight and lowers the price target from $62 to $60.</p>


Barclays Maintains Equal-Weight on Magna International, Lowers Price Target to $60

<p>Barclays  analyst Michael Leithead   maintains LyondellBasell Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>) with a Equal-Weight and raises the price target from $100 to $104.</p>


Barclays Maintains Equal-Weight on LyondellBasell Industries, Raises Price Target to $104

Notable earnings before Thursday's open

Appian Q1 2024 Earnings Preview

Appian reports mixed Q1 results; initiates Q2 and updates FY24 outlook

Appian Corporation (APPN) Q1 2024 Earnings Call Transcript

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Appian</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/appn-stock-quote/"><strong>APPN</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Appian reported earnings per share of -24 cents. This was below the analyst estimate for EPS of -16 cents.</li><li>The company reported revenue of $149.84 million.</li><li>This was 0.05% better than the analyst estimate for revenue of $149.76 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/appn-stock-earnings-appian-for-q1-of-2024/">APPN Stock Earnings: Appian Misses EPS, Beats Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

APPN Stock Earnings: Appian Misses EPS, Beats Revenue for Q1 2024

William Blair analyst Jake Roberge has maintained their bullish stance on APPN stock, giving a Buy rating on April 17. Jake Roberge has given his B...

Appian's Solid Performance and Promising Outlook Merit a Buy Rating: Analyst Jake Roberge's Perspective

Appian (APPN – Research Report), the Technology sector company, was revisited by a Wall Street analyst today. Analyst Kevin Kumar from Goldman Sach...

Appian's Resilience Amid Challenges: A Positive Outlook for Long-Term Growth

KeyBanc analyst Thomas Blakey maintained a Buy rating on Appian (APPN – Research Report) today. The company's shares closed yesterday at $31.03. Bl...

KeyBanc Sticks to Its Buy Rating for Appian (APPN)

Companies in the Technology sector have received a lot of coverage today as analysts weigh in on Axcelis Technologies (ACLS – Research Report), App...

Analysts Offer Insights on Technology Companies: Axcelis Technologies (ACLS), Appian (APPN) and Cohu (COHU)

Steve Enders, an analyst from Citi, maintained the Buy rating on Appian (APPN – Research Report). The associated price target was lowered to $42.00...

Buy Rating Affirmed: Appian's Growth Potential and Resilience Amid Currency Challenges

ABUS

ACDVF

ACLLF

ACLS

AGCO

AGIO

ALNY

AMKBY

APTV

ARES

ARHS

ATGFF

ATUS

AVNS

AXGN

BPMC

BRKR

CCRD

CDUAF

CNHI

COHU

CPSH

CRTO

CYBR

DNNGY

DRVN

EDVMF

ENOV

EXLS

FLWS

FTDR

GERN

GMAB

HIPO

IDCC

INMD

IRMD

ITRI

Press Releases

Appian to Host Investor Day at Appian World on April 16

Announcing ProcureSight for Better, Faster Government Procurement

Contracts

Appian Signs a Strategic Collaboration Agreement with AWS to Deliver Private AI for End-to-End Process Automation

TELUS International and Appian Expand Strategic Partnership to Help Companies Simplify Complex Business Processes Through an Innovative, Low-Code Automation Platform

Latest Version of Appian Platform Orchestrates Change through AI Process Automation that Moves Business Forward

2024 Appian Innovation Award Winners Demonstrate Significant Business Results with Next-Gen AI Process Automation

Appian Celebrates 2024 Partner Award Winners for Moving Businesses Forward with Process Automation

Appian To Announce First Quarter 2024 Financial Results on May 2

Appian Announces First Quarter 2024 Financial Results

Appian Named a Leader in the 2024 Gartner® Magic Quadrant™ for Process Mining Platforms Report

TIXT

TSX:TIXT

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Appian Stock (NASDAQ:APPN), Short Interest Report

People Also Watch